Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
Harwood Feffer LLP Announces Investigation Of Tobira Therapeutics, Inc. Tobira Therapeutics Reaches Analyst Target Price. In recent trading, shares of Tobira Therapeutics Inc have crossed above the average analyst 12-month target price of $19.00, changing hands for $38.91/share.